



BEACON NEWS

New Members and Events

BEACON Welcomes Fish & Richardson

Fish & Richardson is a leading global law firm practicing in the areas of intellectual property and litigation.



FISH & RICHARDSON

Founded in 1878, the firm has prosecuted and litigated many of the fundamental patents of an industrializing

America: the telephone, the airplane, the light bulb, and the radio. Today, with over 375 attorneys and technology specialists, the firm continues to be the go-to IP firm for great innovators in cutting-edge technologies. Fish uses its deep technical and legal expertise, along with strategic business insight, to serve clients who value intellectual property.

Attorneys at Fish have substantial experience in the medical device arena, including prosecuting patents, leading due diligence teams, and handling significant patent infringement litigation on behalf of their clients.

They offer a broad spectrum of freedom-to-operate services tailored to clients' needs, including comprehensive studies for clearance of products to be released on the market, as well as landscape studies to guide companies so they safely develop medical devices without running afoul of existing patents.

They also provide freedom-to-operate advice and a variety of other services to venture fund clients in connection with potential investments.

Through their Drug and Medical Device Regulatory practice, they assist medical device companies with FDA and regulatory work, including counseling on FDA test procedures and reporting requirements, import rules, and labeling requirements.

They have prosecuted and litigated patents on the following:

- Atomic force microscopes
- Cardiac pacing and defibrillation devices
- Catheters (for use in drug delivery, diagnostic applications, and surgical protocols)
- Cerebrospinal fluid shunt valves
- Devices for magnetic resonance imaging, ultrasound, and X-ray imaging
- Dialysis equipment
- Drug delivery devices
- Endoscopes
- Peritoneal dialysis machines
- Prosthetic organs and joints and orthopedic devices
- Surgical instruments (for use in atherectomy and arthroscopy)
- Suture anchors used in orthopedic surgery

For further information visit www.fr.com or contact Attorney Michael Siem at 212-765-5070.

BEACON Welcomes Career Network for Science PhDs at Yale (CNSPY)

BEACON welcomes a new partner organization to the network – Career Network for Science PhDs at Yale (CNSPY). This is a student-run organization committed to advancing careers for science PhDs at Yale who are interested in entering non-academic careers. Their goal is to use various networks in the region that would be willing to talk with potential PhD candidates about their future opportunities in various levels of science and possibly find them internships.

They are also going to market BEACON events to those who might like to attend and network. Joe Bronzino has been listed on the faculty adviser page on the website as someone they can contact. Beacon looks forward to meeting some of the members of CNSPY at future events. For further information about this organization or to talk with them about finding an intern for your company, visit www.careernetworkforsciencephds.org or contact Thihan Padukkavidana, Ph.D., Yale University School of Medicine at Thihan.padukkavidana@yale.edu

**2012 BEACON SEMINAR #1:
THE PROMISE OF REGENERATIVE
PHARMACOLOGY: STIMULATING THE BODY TO
HEAL ITSELF - WEDNESDAY, FEBRUARY 29, 2012**



**Presented by: J. Koudy Williams,
Professor, Wake Forest
University Institute for
Regenerative
Medicine, Wake Forest
University Health Sciences,
Winston-Salem, NC**

Dr. J. Koudy Williams (DVM) is a veterinary scientist and Professor of Regenerative Medicine at the Wake Forest Institute for Regenerative Medicine. His research focuses on the use of translational animal models, including nonhuman primates, to provide data for clinical development of regenerative medicine approaches to the treatment of chronic diseases affecting both men and women in the United States and around the world. These research focus areas include cell therapy and tissue engineering approaches for cardiovascular diseases, diabetes, corneal regeneration and regeneration of the genitourinary system. Stem cell-based therapy and Bioengineered organs are the best documented approaches in regenerative medicine, promising cures for a multitude of diseases and disorders. However, the *ex vivo* expansion of stem cells and their *in vivo* delivery are restricted by the limited availability of stem cell sources, the excessive cost of commercialization, and the anticipated difficulties of clinical translation and regulatory approval. Similarly, bioengineered organs require stem cell sources, complex seeding and pre-conditioning

paradigms. An alternative to regenerate organs and tissues are cell populations already present in a patient's body, including stem/progenitor cells, which can be actively attracted to sites of injury. This technique, known as endogenous cell homing, has the potential to provide new therapeutic options for *in situ* tissue regeneration. Such options would be less costly and complex than approaches that require substantial *ex vivo* cell manipulation and that use artificial vehicles for cell delivery. Tissue regeneration methods that rely on endogenous stem/progenitor cell homing, local tissue responses, and functional stimulation thus offer new insights into *in vivo* tissue engineering and hold great promise for the future of translational medicine. Although such methods that take advantage of the latent endogenous regenerative potential of the patient are promising for the repair of damaged tissue, they are in need of further experimental support before application in late-stage diseases or severe tissue injury. This includes a better understanding of the basic biology involved in cell homing and development of viable methods to attract endogenous stem cells to the site of injury. This review will highlight some of these approaches to diseases common to a large population of patients in the United States and around the world. In the future, these exciting paradigms are likely to help reconcile the clinical and commercial pressures in regenerative medicine.

DATE: Wednesday, February 29, 2012
TIME: Networking 5:30-6:30 PM Presentation 6:30-7:30 PM
**PLACE: UConn Health Center, Patterson Auditorium
(Academic Entrance) 263 Farmington Avenue, Farmington**
NO CHARGE TO ATTEND, BUT RSVP REQUIRED
RSVP to: 860-547-1995 or toll free: 877-723-2266
Email: twilson@beaconalliance.org

BEACON

One Congress Street,
Suite 201, Hartford, CT 06114
(860) 547-1995 Toll-free: (877) 723-2266
Fax: (860) 727-0311

Find BEACON on LinkedIn!

Contact us on Skype: [terriwilson1960](https://www.skype.com/user/terriwilson1960)

President & Founder: Joseph Bronzino

Co-Executive Directors: Terri Wilson & Donald Peterson

Program Assistant: Leonor Snow

www.beaconalliance.org

BEACON 2012 Members

Benefactors: Trinity College; Covidien Vascular Therapies; Covidien Surgical Devices; Saint Francis Hospital and Medical Center

Medical/Academic Members: Connecticut VA Health Care Center Clinical Engineering Department; University of Hartford; Springfield Technical Community College; Asnuntuck Community College; Medical Professions and Teacher Academy; Hartford Hospital; Hospital for Special Care; Connecticut Children's Medical Center; University of Connecticut and Medical Center

Corporate Members: Cable Components Group; Cardio Pulmonary Corporation; Connecticut Innovations; Court Square Group; Covington Associates; Dymax Corporation; Foster Corporation; Joining Technologies; Metrum Research Group; CL&P and Yankee Gas; Putnam Plastics; Rogers Corporation; Silex Medical, LLC; Soft Tissue Regeneration, Inc.; Valtronic Technologies; Web Industries

Legal Members: Fish & Richardson LLC; McCormick, Paulding & Huber LLP; Robinson & Cole LLC

MISSION STATEMENT

BEACON (the Biomedical Engineering Alliance & Consortium) is a non-profit 501(c)(6) trade organization comprised of academic and medical institutions, as well as corporations and entrepreneurs dedicated to the development and commercialization of new medical devices and technology.